HAEM5:ALK-negative anaplastic large cell lymphoma: Difference between revisions
| [pending revision] | [pending revision] |
| Line 500: | Line 500: | ||
|Yes | |Yes | ||
|No | |No | ||
|Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | | | ||
* Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | |||
* Ruxolitinib may be used to target JAK-STAT pathway (not FDA-approved) | *Ruxolitinib may be used to target JAK-STAT pathway (not FDA-approved)<ref name=":13" /> | ||
|- | |- | ||
|''JAK1'' | |''JAK1'' | ||
| Line 512: | Line 513: | ||
|Yes | |Yes | ||
|No | |No | ||
|Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | | | ||
* Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | |||
|- | |- | ||
|PRDM1/BLIMP1<ref name=":5" /> | |PRDM1/BLIMP1<ref name=":5" /> | ||